Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Critical Medical Devices

Nurse-practitioner-founded device start-up designing a multi-drug emergency IV pump with protocol-guided dosing safeguards.

McCall (Idaho), United States, North AmericaMedTech & devices, Multi-drug emergency IV pumpBoise (Idaho) – Trailhead
Stage
Pre-seedNo documented AI
Product
R&DNone known
Funding raised
$324Kdisclosed
Founded
20260 years ago
Founders
1Chantell
Global score
3.0Grade DRank 126 of 151

Overview

Medical device company founded by a nurse practitioner, developing the Anchor IV Pump, a smart multi-drug IV delivery platform to reduce medication errors in emergency care.

Traction

None known

No public evidence of traction found: pump shown as a concept visual; funds intended for R&D, clinical validation and the FDA pathway.

Market

Infusion pumps

Infusion pumps are bought by hospitals, emergency departments and EMS, where medication errors in emergencies are a leading safety issue. Buyers want devices that reduce errors without slowing care and integrate with existing workflows. Purchasing goes through value-analysis committees, GPOs and FDA-cleared vendors. New entrants face high regulatory and clinical-evidence bars.

Addressable market

2025
$12.8B
2030
$18.3B
+7.4% a year

Infusion pumps: $12.8bn in 2025, 7.4% CAGR (Persistence Market Research).

Customers

Emergency departments, ICUs, EMS and critical-care transport, military medicine

Who signs the cheque

Hospital value-analysis committees, GPOs, nursing and pharmacy leadership

Geographies

  • United States

Drivers

  • Medication-error reduction programmes
  • Staffing shortages increasing workload
  • Demand for protocol-guided emergency care

Headwinds

  • Concept stage
  • Heavy regulation (FDA class II/III)
  • Incumbent pump makers

Persistence Market Research values infusion pumps at $12.8bn in 2025 (7.4% CAGR through 2032); 2030 extrapolated ~$18.3bn; range $8.7–21bn.

Scalability 4/10. Hardware IV pump subject to FDA clearance then national approvals, facing established leaders (BD, Baxter, ICU Medical).

Market source: persistencemarketresearch.com

Technology

Category

Medical device (infusion)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

The Anchor IV Pump is a smart multi-channel pump with protocol-guided workflows and built-in dosing safeguards for emergency care. It is currently a concept visual with R&D funded.

Moat

Clinician-derived workflow design; IP not documented. Moat would come from FDA clearance and clinical evidence.

Differentiation

Multi-drug, protocol-driven emergency use versus single-channel general pumps.

Integration points

  • Hospital EHR and drug libraries
  • Emergency protocols
  • Drug-delivery device partners

Depends on

  • FDA clearance
  • Contract manufacturing
  • Drug library and protocol validation

Use of AI

No use of AI mentioned

Product in detail

Smart multi-channel infusion pump with protocol-guided workflows and built-in dosing safeguards.

Business

Model
Planned device sales plus disposables to hospitals and EMS.
Revenue logic
Capital device plus per-use sets; pricing not defined.
Go-to-market
Not yet defined; would use GPOs and clinical champions.

Next milestones

  1. Close of the $1.5M pre-seed
  2. Working prototype
  3. FDA pre-submission meeting

Key risks

  • Funding shortfall ($0.3M of $1.5M)
  • Regulatory pathway cost
  • Competition from incumbents

Opportunities

4 found in the network

Concrete moves for Critical Medical Devices inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 1
  • Investors 2
  • Peers 1

Co-development1

An integration or joint product

Learn from Byonyks' FDA 510(k) and manufacturing path

Byonyks has taken a class II fluid-delivery device through FDA 510(k) and built a manufacturing base, exactly the path ahead for Critical Medical Devices. A mentoring or engineering-services arrangement shortens time to clearance.

25%confidence

Evidence from the records

  • “FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
  • “DRAP-approved factory in Pakistan”
  • “Very high risk: R&D, FDA class II/III pathway and $0.3M raised.”
If it works
A faster, cheaper regulatory and manufacturing roadmap.
First step
Request a call with Byonyks' regulatory lead on predicate selection and testing.

Investors2

A fund whose thesis fits

Fill the pre-seed gap with Robin Hood Ventures

Robin Hood Ventures is a US angel network writing $0.25–0.5M at pre-seed/seed in HealthTech and life sciences, sized for the $1.2M still missing. It backed network member Vytala Health, giving a warm path.

30%confidence

Evidence from the records

  • “$323,500 raised (against a $1.5M pre-seed target)”
  • “Clinician founder”
If it works
A meaningful share of the remaining pre-seed.
First step
Ask Vytala Health's founders for an introduction and send the clinical problem brief.

Apply to gener8tor for a $100K cheque and programme

gener8tor invests $0.1M at pre-seed/seed in US HealthTech and deep tech and backed network member Chonex. It suits a first institutional cheque and accelerator support.

30%confidence

Evidence from the records

  • “Pre-seed (in progress)”
  • “Real safety problem”
If it works
Accelerator capital and investor network to close the round.
First step
Ask Chonex's CEO for a reference and apply to the next gener8tor cohort.

Peers1

Founders solving the same problem elsewhere

Share drug-delivery device lessons with Love Lifesciences

Both are US pre-seed drug-delivery device companies founded around a clinical pain point. Exchanging contract manufacturer, regulatory consultant and pharma-partnering contacts saves both time and money.

30%confidence

Evidence from the records

  • “UniPen universal injector pen compatible with standard vials, for self-administration of drugs.”
  • “Smart multi-channel infusion pump with protocol-guided workflows and built-in dosing safeguards.”
If it works
Shared vendors and faster partner introductions.
First step
Set a founders' call to swap vendor lists.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

US federal biomedical research agency funding biotech, health and medtech via SBIR and research grants (Defined Bioscience, Microvitality, Corticale).

US emergency multi-drug IV pump.

40%confidence

Evidence from the records

  • “MedTech & devices”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
First step
Apply SBIR.

Philadelphia angel group of ~35 serial entrepreneurs investing $250K-$500K first cheques in B2B software, healthcare, education IT and life sciences.

Nurse-practitioner-founded emergency IV pump at pre-seed: healthcare device matching the angels' sectors, but FDA hardware needs syndication beyond one cheque.

35%confidence

Evidence from the records

  • “Multi-drug emergency IV pump”
  • “Pre-seed”
First step
Propose a syndicated round with a clear FDA pathway budget.

US accelerator network investing $100,000 per startup through 12-week programmes across climate, health, agri, fintech and deep tech.

US pre-seed medtech (multi-drug emergency IV pump) — fits 'HealthTech' and the stage, but device regulatory timelines are long relative to a 12-week programme.

40%confidence

Evidence from the records

  • “"HealthTech"”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Chonex (network portfolio company of gener8tor).
First step
Check whether a gener8tor health programme is open and frame a regulatory milestone.

Zero-equity nonprofit accelerator (since 2009) running corporate-funded programmes in Boston, Dallas, Jerusalem, Lausanne and London.

US emergency IV pump — health.

35%confidence

Evidence from the records

  • “HealthTech”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Monte Caldera Technologies Inc. (network portfolio company of MassChallenge).
First step
Apply.

US accelerator with no public profile in our data; supported maternal-health medtech Lidavex.

US pre-seed emergency IV pump — early medtech like Lidavex.

30%confidence

Evidence from the records

  • “Lidavex”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Gust Accelerator).
First step
Ask Lidavex for programme details.

US accelerator with no profile in our data; supported maternal-health medtech Lidavex.

US emergency IV pump.

30%confidence

Evidence from the records

  • “Lidavex”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Octane LaunchPad).
First step
Ask Lidavex.

US angel network investing at pre-seed and seed; backed Vytala Health's $805K pre-seed in medical nutrition.

US pre-seed emergency IV pump — health device at angel stage.

30%confidence

Evidence from the records

  • “"Pre-seed","Seed"”
  • “Multi-drug emergency IV pump”
  • “No public evidence of traction found: pump shown as a concept visual”
Intro path
Founder-to-founder intro via Vytala Health (network portfolio company of JumpStart NJ Angel Network).
First step
Ask Vytala for a referral.

San Francisco pre-seed firm (Charles Hudson, $250M+ AUM, 500+ companies) backing people over product, often before traction.

Nurse-practitioner founder building a multi-drug emergency IV pump: strong founder-market fit, but FDA hardware is capital-heavy for a $0.5M cheque.

25%confidence

Evidence from the records

  • “Multi-drug emergency IV pump”
  • “Medical device company founded by a nurse practitioner”
First step
Pitch only with a staged, capital-light regulatory plan.

Investment analysis

3.0D

Grade D

Rank 126 of 151

Disruption5.0/10
Business model1.0/10
Market4.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early to invest.

Disruption

5/10

Multi-drug IV pump to reduce errors: product innovation in an established category.

Business model

1/10

Concept visual only, no traction.

Market

4/10

Score 4/10: TAM $12.8bn → base 5; scalability 4/10 (−1); no commercial presence in ≥2 countries yet (0).

Risk

9/10

Lower is better

Very high risk: R&D, FDA class II/III pathway and $0.3M raised.

Strengths

  • Clinician founder
  • Real safety problem

Risks

  • Concept stage
  • Heavy regulation

Funding

$324K, disclosed
  1. 2026-05

    Pre-seed (in progress)$323,500 (of $1.5M targeted)

    not disclosed

  2. 2026-06

    Prize (Startup World Cup Boise winner)qualification for the final

    Startup World Cup

Amount used in the study. $323.5K actually raised against a $1.5M target (remainder excluded).

Note. $323,500 raised ($1.5M pre-seed target)

verified, nothing to correct (website: ANCHOR pump in development, concept visuals, pre-seed of $323,500 of $1.5M as of May 2026).

Team

  • Chantell Williams, MSN, FNP-C

    Founder & CEO

    Family Nurse Practitioner who designed the Anchor IV Pump based on her clinical experience.

Sources

Regional final
Boise (Idaho) – Trailhead
Identification confidence
high
Founding year: 2026 (low confidence)
Gust indicates founding in January 2026; but the website shows "© 2025", so activity possibly as early as 2025. gust.com
  1. 1idahobusinessreview.com/2026/06/01/critical-medical-devices-wins-boise-startup-worl
  2. 2criticalmedicaldevices.com/
  3. 3gust.com/companies/critical-medical-devices

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet